Soft Tissue Lesions of the Vulva and Vagina
Carlos Parra-Herran,Marisa R. Nucci
DOI: https://doi.org/10.1016/b978-0-323-44732-4.00009-1
2018-01-01
Abstract:Vulvovaginal mesenchymal neoplasms and non-neoplastic proliferations are rare. Nonetheless, the spectrum of lesions is wide. A major subset includes tumors preferentially seen in this anatomic location (vulvovaginal stromal tumors). Among them, the only one with propensity for aggressive behavior and recurrence is deep (aggressive) angiomyxoma; others are, by comparison, more indolent. With the exception of superficial angiomyxoma, vulvovaginal stromal tumors express hormone receptors, which has been implicated in their pathogenesis. Given the morphologic overlap among most primary vulvovaginal stromal lesions, an immunohistochemical panel including estrogen receptor, desmin, smooth muscle actin and CD34 is commonly performed. However, overlap in marker expression also occurs, and the diagnosis needs to rely in a combination of clinical, pathologic and immunophenotypic features. In ambiguous cases, an effort should be made to at least exclude deep angiomyxoma. Most fibrohystiocytic, lipomatous, muscular, vascular and neural lesions involving the distal female genital tract are morphologically identical to their extragenital counterparts. Important exceptions exist: for instance, criteria for classification of smooth muscle neoplasms as benign, malignant or of low malignant potential is specific for vulvovaginal lesions, and differs from uterus or other soft tissue locations. Many tumors harbor distinctive translocations or other genomic alterations, for example: FOXO1 monoallelic loss (cellular angiofibroma, mammary-type myofibroblastoma), COL1A1-PDGFB chimeric fusion (dermatofibrosarcoma protruberans), FUS-BBF2H7 fusion (low grade fibromyxoid sarcoma) and EWS alterations (angiomatoid fibrous histiocytoma, Ewing sarcoma). When available, molecular testing should be considered if tumors with specific genomic abnormalities are in the differential.